Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Acquisitions & Divestments (2021 - 2025)

Historic Change in Acquisitions & Divestments for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $32.9 million.

  • 4D Molecular Therapeutics' Change in Acquisitions & Divestments fell 4923.92% to $32.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $367.0 million, marking a year-over-year increase of 17859.45%. This contributed to the annual value of $169.0 million for FY2024, which is 247.5% down from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $32.9 million for Q3 2025, which was down 4923.92% from $101.6 million recorded in Q2 2025.
  • In the past 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments registered a high of $205.3 million during Q3 2022, and its lowest value of -$135.2 million during Q4 2022.
  • Over the past 5 years, 4D Molecular Therapeutics' median Change in Acquisitions & Divestments value was $44.2 million (recorded in 2023), while the average stood at $49.8 million.
  • In the last 5 years, 4D Molecular Therapeutics' Change in Acquisitions & Divestments tumbled by 280388.0% in 2022 and then soared by 102788.31% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Change in Acquisitions & Divestments stood at $5.0 million in 2021, then tumbled by 2803.88% to -$135.2 million in 2022, then surged by 121.09% to $28.5 million in 2023, then surged by 130.72% to $65.8 million in 2024, then plummeted by 49.95% to $32.9 million in 2025.
  • Its last three reported values are $32.9 million in Q3 2025, $101.6 million for Q2 2025, and $166.7 million during Q1 2025.